Squamous Cell Carcinoma of Head and Neck: all 1,711 studies

Page 10 of 18. Open to participants first (544), then studies with results posted, then the rest; newest registration first within each.

• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCCCompletedNCT06236425Phase 1
• CD40 Agonist and PD-1 Inhibitor in HNSCCActive, not recruitingNCT06159621Phase 1
• A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsTerminatedNCT06158958Phase 1
• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingNCT06147037Phase 1
• Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic SurgeryCompletedNCT06112535Not applicable
• Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck CancerTerminatedNCT06110195Phase 1
• Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell CarcinomasStatus unknownNCT06109207Phase 1
• Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral MucosaCompletedNCT06094829
• A Window of Opportunity Study of Black Raspberry for Patients With HNSCCWithdrawnNCT06086925Early Phase 1
• Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck CancerWithdrawnNCT06084845Phase 2
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06082167Phase 2/3
• Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCCActive, not recruitingNCT06081673Phase 2
• PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCCCompletedNCT06062602Early Phase 1
• A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingNCT06062420Phase 2
• People Living With HIV, Oral and Oropharyngeal Cancer, and Health EquityActive, not recruitingNCT06055868
• Study of ALE.C04 in Patients With Head and Neck CancerTerminatedNCT06054477Phase 1/2
• Needs and Preferences of Patients With Head-neck Cutaneous SCCActive, not recruitingNCT06046625
• Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell CarcinomaStatus unknownNCT06041464
• Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesTerminatedNCT06034860Phase 1
• Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy StudyCompletedNCT06031337
• Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell CarcinomaStatus unknownNCT06023875Phase 2
• Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)TerminatedNCT06022757Phase 1/2
• Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)Active, not recruitingNCT06009861Phase 2
• Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose RadiotherapyActive, not recruitingNCT05992610Not applicable
• A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsTerminatedNCT05983133Phase 1
• TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT05980598Phase 2
• Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT05980000Phase 2
• Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).Active, not recruitingNCT05977907Phase 2
• Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre ExperienceCompletedNCT05950737Not applicable
• Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck CancerCompletedNCT05936502
• Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous ExaminationCompletedNCT05935995Not applicable
• Contribution of Residual Tumour DNA Testing on the Surgical BedActive, not recruitingNCT05934929Not applicable
• Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid CancerActive, not recruitingNCT05931445Not applicable
• Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck CancerTerminatedNCT05930938Phase 3
• Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing RadiotherapyCompletedNCT05918224Phase 2
• GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05913388Phase 2
• A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05904496Phase 1
• Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid TumorsActive, not recruitingNCT05902520Phase 1
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsActive, not recruitingNCT05867303Phase 1
• Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsCompletedNCT05858736Phase 1
• Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT05845632
• Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT05845307Early Phase 1
• Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.Status unknownNCT05832593
• Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedNCT05827614Phase 1
• Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell CarcinomaCompletedNCT05821179
• Pilot Study of Imatinib Cetuximab Combo for H & N CancerCompletedNCT05816785Early Phase 1
• NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHNCompletedNCT05802290Phase 3
• Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell CarcinomaStatus unknownNCT05798793Phase 3
• A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and VomitingCompletedNCT05792228Not applicable
• Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05784012Phase 1/2
• Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05783622Phase 1
• Oral Microbioma and Oral Malignant DiseaseStatus unknownNCT05766150
• A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell CarcinomaStatus unknownNCT05749042Phase 2
• 3D Specimen Maps for RT PlanningActive, not recruitingNCT05743569
• Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHNWithdrawnNCT05743270Phase 2
• Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)Active, not recruitingNCT05724329Phase 2
• Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT05721755Phase 3
• Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCCCompletedNCT05721443Phase 2
• The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124CompletedNCT05708209
• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).Active, not recruitingNCT05681039Phase 2
• A Phase 1b Study of WU-NK-101 in Combination With CetuximabActive, not recruitingNCT05674526Phase 1
• Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC PatientsCompletedNCT05673577Phase 2
• Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)WithdrawnNCT05668949Phase 1/2
• A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05668858Phase 1/2
• A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid TumorsActive, not recruitingNCT05653882Phase 1
• Post-Operative Radiotherapy De-Escalation of Negative Nodal Regions in Head and Neck Squamous Cell CarcinomaStatus unknownNCT05650034Not applicable
• Study of CHS-114 in Participants With Advanced Solid TumorsActive, not recruitingNCT05635643Phase 1
• Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2
• Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma PatientsStatus unknownNCT05611463Phase 2
• Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCCWithdrawnNCT05608369Phase 2
• A Study of [225Ac]-FPI-2059 in Adult Participants With Solid TumoursTerminatedNCT05605522Phase 1
• Study of DF9001 in Patients With Advanced Solid TumorsCompletedNCT05597839Phase 1/2
• Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsCompletedNCT05585034Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT05581004Phase 1
• Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene CopolymerplasmidCompletedNCT05578820Phase 1
• Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell CarcinomaStatus unknownNCT05578170
• Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced MalignanciesCompletedNCT05577182Phase 1
• A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsTerminatedNCT05576077Phase 1
• Vitamin-D Receptor in Laryngeal Squamous Cell CarcinomaStatus unknownNCT05568641
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasActive, not recruitingNCT05565417Phase 1/2
• 89Zr-girentuximab for PET Imaging of CAIX Positive Solid TumorsTerminatedNCT05563272Phase 2
• SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownNCT05552807Phase 1
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck CancerActive, not recruitingNCT05540899Phase 1
• A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsCompletedNCT05538572Phase 1
• A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid TumorsActive, not recruitingNCT05537740Phase 1
• Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT05527782Phase 2
• Toripalimab-based Neoadjuvant Therapy in LA-HNSCCActive, not recruitingNCT05522985Phase 2
• Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)Active, not recruitingNCT05520099
• Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCCompletedNCT05516589Phase 2
• Real-time Margin Assessment in Head and Neck CancerCompletedNCT05499065Phase 2
• Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck RegionCompletedNCT05482880
• Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell CarcinomaStatus unknownNCT05476965Phase 2
• Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck CancerWithdrawnNCT05472506Phase 1
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminatedNCT05462873Phase 1
• Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCCActive, not recruitingNCT05459415Not applicable
• The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients with Head and Neck Cancer Undergoing Radiation TherapyTerminatedNCT05457478Not applicable

← Squamous Cell Carcinoma of Head and Neck overview